These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22433611)

  • 81. Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
    Van den Mooter L; Caerels S; Mathieu C
    Expert Opin Pharmacother; 2018 Apr; 19(6):617-622. PubMed ID: 29537892
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 84. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
    Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
    Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
    Pallarés V; Escobar C; Egocheaga I; Obaya JC
    Semergen; 2021 Dec; 47 Suppl 1():1-4. PubMed ID: 34776344
    [TBL] [Abstract][Full Text] [Related]  

  • 86. An update on dapagliflozin for chronic kidney disease.
    Kelly MS
    Drugs Today (Barc); 2022 Feb; 58(2):69-75. PubMed ID: 35188141
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
    DeFronzo RA; Hompesch M; Kasichayanula S; Liu X; Hong Y; Pfister M; Morrow LA; Leslie BR; Boulton DW; Ching A; LaCreta FP; Griffen SC
    Diabetes Care; 2013 Oct; 36(10):3169-76. PubMed ID: 23735727
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Parkinson J; Tang W; Johansson CC; Boulton DW; Hamrén B
    Diabetes Obes Metab; 2016 Jul; 18(7):685-92. PubMed ID: 27299483
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
    Kasichayanula S; Chang M; Liu X; Shyu WC; Griffen SC; LaCreta FP; Boulton DW
    Adv Ther; 2012 Feb; 29(2):163-77. PubMed ID: 22271159
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dapagliflozin (Forxiga) for type 2 diabetes?
    Drug Ther Bull; 2013 Sep; 51(9):105-8. PubMed ID: 24030968
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis.
    Jiang L; Jia Y; Wang X; Wang Z; Lv X; Jia Y; Feng Y; Yin H; Yan M; Fan X; Liu Y
    Expert Opin Drug Saf; 2023; 22(5):407-416. PubMed ID: 36608279
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
    Melin J; Tang W; Rekić D; Hamrén B; Penland RC; Boulton DW; Parkinson J
    J Clin Pharmacol; 2022 Oct; 62(10):1227-1235. PubMed ID: 35403243
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
    Busse D; Tang W; Scheerer M; Danne T; Biester T; Sokolov V; Boulton D; Parkinson J
    Br J Clin Pharmacol; 2019 Aug; 85(8):1820-1828. PubMed ID: 31077437
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
    Naagaard MD; Chang R; Någård M; Tang W; Boulton DW
    Br J Clin Pharmacol; 2022 Feb; 88(4):1942-1946. PubMed ID: 34687551
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes.
    Sadurní A; Kehr G; Ahlqvist M; Wernevik J; Sjögren HP; Kankkonen C; Knerr L; Gilmour R
    Chemistry; 2018 Feb; 24(12):2832-2836. PubMed ID: 29211300
    [TBL] [Abstract][Full Text] [Related]  

  • 96. FDA rejects novel diabetes drug over safety fears.
    Burki TK
    Lancet; 2012 Feb; 379(9815):507. PubMed ID: 22334883
    [No Abstract]   [Full Text] [Related]  

  • 97. Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
    Elbeddini A; Tayefehchamani Y; Davey M; Gallinger J; Hooda N; Aly A; Erickson D; Lee S
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526523
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Challenges for the treatment of diabetes mellitus.
    Papazafiropoulou AK; Kardara MS; Pappas SI
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):203-9. PubMed ID: 21913881
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Diabetes: Efficacy of dapagliflozin associated with renal function.
    Kirk R
    Nat Rev Endocrinol; 2013 Dec; 9(12):688. PubMed ID: 24126478
    [No Abstract]   [Full Text] [Related]  

  • 100. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
    Gould JC; Kasichayanula S; Shepperly DC; Boulton DW
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):89-97. PubMed ID: 23851069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.